JAK Inhibitors and Endothelial Cardiovascular Risk

Cardiovascular safety signals associated with JAK inhibitors have raised an important mechanistic question: do different agents produce similar vascular effects, or does their kinase selectivity create distinct endothelial response profiles? The reference study by Zavoriti and Miossec addresses this question using a controlled human endothelial-cell model exposed to combined tumor necrosis factor (TNF) and interleukin-17A (IL-17A). Rather than measuring inflammation alone, the investigators examined inflammatory mediators, adhesion molecules, coagulation and fibrinolysis-related genes, and apoptosis.

Published in ACR Open Rheumatology, the study is especially relevant to immune regulation research and inflammatory disorder research because rheumatoid arthritis-associated cardiovascular risk occurs in a background of persistent cytokine exposure. Its central message is nuanced: all tested JAK inhibitors reduced one inflammatory output, IL-6, but several agents failed to correct—and at higher in vitro concentration intensified—endothelial changes associated with leukocyte recruitment and vascular activation.

Study Background and Research Question

Patients with rheumatoid arthritis have a higher incidence of cardiovascular disease than the general population, a relationship commonly linked to chronic systemic inflammation. TNF and IL-17A are particularly relevant to vascular biology. IL-17A is a signature cytokine of Th17 cells, while TNF can amplify IL-17A-driven endothelial activation. Together, these cytokines promote IL-6 and IL-8 production, increase VCAM-1, ICAM-1, and E-selectin, induce tissue factor, suppress thrombomodulin, and can promote endothelial apoptosis.

The reference study also places these findings in the context of the JAK-STAT signaling pathway. Cytokines such as IL-6, IL-23, and interferon-γ directly use JAK-STAT signaling, whereas TNF and IL-17A do not directly signal through this pathway. This distinction matters: a JAK inhibitor may alter the endothelial response to a cytokine-rich environment without directly blocking the initiating TNF or IL-17A receptors.

The research question was therefore comparative and functional: how do tofacitinib, baricitinib, upadacitinib, peficitinib, ruxolitinib, and fedratinib affect endothelial inflammation, adhesion, coagulation-related gene expression, and apoptosis under combined TNF and IL-17A stimulation?

Key Innovation from the Reference Study

The main innovation is the separation of endothelial anti-inflammatory activity from broader vascular safety-relevant outcomes. A reduction in IL-6 may appear beneficial, but it does not by itself demonstrate that an endothelial monolayer has regained an anticoagulant, nonadhesive, and viable phenotype. The investigators therefore evaluated several response layers in the same experimental system.

This design reveals differences that would be missed by a single cytokine assay. For example, an inhibitor could lower IL-6 while leaving thrombomodulin suppression unchanged or increasing adhesion molecule expression. The study consequently avoids a simple “anti-inflammatory equals vascular protective” interpretation. It instead presents JAK inhibitor effects as a multidimensional phenotype that depends on inhibitor identity, concentration, and biological endpoint.

The work is also useful for interpreting lymphocyte proliferation inhibition and other established pharmacological activities in relation to vascular biology. Effects observed in endothelial cells should not be assumed to mirror effects in lymphocytes, where JAK-dependent cytokine signaling is central to proliferation, differentiation, survival, and immune regulation.

Methods and Experimental Design Insights

Human vascular endothelial cells were exposed to a high-inflammatory combination of TNF and IL-17A. The cells were then treated or not treated with six JAK inhibitors: tofacitinib, baricitinib, upadacitinib, peficitinib, ruxolitinib, and fedratinib. Each compound was tested at 1 or 10 μM, allowing the investigators to examine both inhibitor-specific and concentration-dependent effects. The complete treatment framework and outcome data are described in the published article.

Secreted IL-6 and IL-8 were quantified by enzyme-linked immunosorbent assay. Quantitative reverse transcriptase polymerase chain reaction was used to measure genes encoding endothelial adhesion molecules and components of coagulation and fibrinolysis pathways. Annexin V staining provided an apoptosis readout, while cytotoxicity observations helped distinguish regulated apoptosis from generalized loss of cell health.

Protocol Parameters

• Inflammatory challenge, literature-backed: Use combined TNF and IL-17A stimulation when reproducing the reference model’s endothelial inflammatory context rather than relying on either cytokine alone.
• JAK inhibitor comparison, literature-backed: The study evaluated tofacitinib, baricitinib, upadacitinib, peficitinib, ruxolitinib, and fedratinib at 1 and 10 μM; these concentrations should be treated as study-specific experimental conditions, not as universal dosing recommendations.
• Secreted mediator analysis, literature-backed: Measure both IL-6 and IL-8 by ELISA because the compounds did not affect these outputs identically.
• Endothelial activation panel, literature-backed: Quantify VCAM-1, ICAM-1, and E-selectin transcripts alongside tissue factor and thrombomodulin to distinguish inflammatory signaling from procoagulant and anticoagulant changes.
• Cell-state control, literature-backed: Include Annexin V staining and a cytotoxicity assessment so that reduced or altered gene expression is not interpreted without considering endothelial viability.
• Workflow suggestion: Preserve vehicle controls, cytokine-only controls, and inhibitor-only controls, and analyze each inhibitor separately across both concentrations. This helps identify concentration-dependent reversals that could be obscured by pooled class-level analysis.

Core Findings and Why They Matter

All six JAK inhibitors reduced IL-6 release from endothelial cells stimulated with TNF plus IL-17A. This shared response confirms that JAK inhibition can suppress at least part of the cytokine-induced inflammatory program in this model. However, IL-8 behaved differently: only baricitinib and fedratinib reduced IL-8 overproduction, and they did so from the lower tested concentration.

Adhesion molecule results exposed stronger divergence. Fedratinib reduced VCAM-1 and E-selectin induction at both concentrations. Tofacitinib reduced ICAM-1 and E-selectin induction at 1 μM. At 10 μM, however, tofacitinib, baricitinib, upadacitinib, peficitinib, and ruxolitinib enhanced the TNF-plus-IL-17A-induced expression of VCAM-1 and ICAM-1. This finding is important because endothelial adhesion molecules facilitate leukocyte attachment and recruitment, processes that can sustain vascular inflammation even when soluble IL-6 is reduced.

The coagulation-related results were similarly selective. Peficitinib and fedratinib reduced tissue factor induction at both concentrations, whereas ruxolitinib did so only at 1 μM. None of the inhibitors prevented the cytokine-induced down-regulation of thrombomodulin, an endogenous anticoagulant molecule. Thus, the tested drugs did not restore the entire balance between procoagulant and anticoagulant endothelial functions.

Cell viability added another layer of distinction. Peficitinib and fedratinib showed proapoptotic and cytotoxic effects in endothelial cells. This does not establish that the same effects occur in patients, but it demonstrates why apoptosis and cytotoxicity should accompany vascular marker measurements in preclinical comparisons.

Taken together, the results argue against using IL-6 suppression as a standalone surrogate for cardiovascular protection. The study supports a more careful interpretation in which inflammatory mediator release, adhesion, tissue factor, thrombomodulin, and viability are evaluated as partially independent endpoints. This approach is relevant to autoimmune disease model development and to mechanistic studies of how JAK selectivity intersects with endothelial responses.

Comparison with Existing Internal Articles

The internal article Comparative Vascular Effects of JAK Inhibitors in Endothelial Inflammation addresses a closely related subject and is useful as a workflow-oriented companion. Its emphasis on comparing inflammatory and procoagulant profiles complements the reference paper’s primary evidence, but the published study should remain the basis for the specific concentration-dependent findings and apoptosis conclusions presented here.

For broader experimental planning, Applied Immune Research with Tofacitinib Citrate: Workflows & Tips provides protocol-focused context for immune modulation experiments. Its practical orientation is distinct from the endothelial comparison: it can help organize assay workflows, whereas the reference study cautions that JAK inhibitor effects must be interpreted across multiple vascular endpoints rather than through a single inflammation marker.

Limitations and Transferability

The findings are mechanistically informative but should not be read as direct estimates of clinical cardiovascular risk. The experiment used cultured human endothelial cells and a defined TNF-plus-IL-17A challenge. It did not reproduce blood flow, vascular architecture, platelet interactions, monocyte recruitment, liver metabolism, tissue distribution, or the adaptive immune environment of rheumatoid arthritis or myeloproliferative neoplasms.

The tested concentrations were in the micromolar range, and in vitro concentrations cannot be translated directly into patient exposure without pharmacokinetic, protein-binding, and tissue-distribution data. The results also do not establish whether endothelial changes are reversible, whether they vary among vascular beds, or whether donor-specific biology changes the response. In addition, mRNA measurements do not always predict surface protein abundance or functional thrombosis outcomes.

These limitations define appropriate transferability. The study is strong for generating comparative hypotheses and for designing endothelial assays that measure inflammation, adhesion, coagulation, and apoptosis together. It is not sufficient on its own to rank clinical cardiovascular risk among JAK inhibitors. Researchers should therefore use the findings to guide orthogonal experiments, including protein-level validation and more physiologically complex vascular models, while avoiding unsupported extrapolation beyond the cited evidence.

Research Support Resources

Researchers can use Tofacitinib citrate (CP-690550 citrate), SKU A4135, to support comparable JAK-inhibition workflows in immune regulation research, endothelial assays, or inflammatory disorder research. Appropriate vehicle controls, concentration-response testing, and parallel measurements of cytokines, adhesion markers, coagulation-associated genes, and cell viability remain essential for interpreting results in the context of the reference study.